In vitro and in vivo characterization of A-796260: A selective cannabinoid CB 2 receptor agonist exhibiting analgesic activity in rodent pain models

British Journal of Pharmacology

Volumn 153, Issue 2, 2008, Pages 390-401

  Yao, B B ^a   Hsieh, G C ^a   Frost, J M ^a   Fan, Y ^a   Garrison, T R ^a   Daza, A V ^a   Grayson, G K ^a   Zhu, C Z ^a   Pai, M ^a   Chandran, P ^a   Salyers, A K ^a   Wensink, E J ^a   Honore, P ^a   Sullivan, J P ^a   Dart, M J ^a   Meyer, M D ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

A 796260; Cannabinoid; CB 2; Inflammatory pain; Neuropathic pain

Indexed keywords

3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; [1 (2 MORPHOLIN 4 YLETHYL) 1H INDOL 3 YL] (2,2,3,3 TETRAMETHYLCYCLOPROPYL)METHANONE; A 796260; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; NALOXONE; UNCLASSIFIED DRUG;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; HYPERALGESIA; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; LOCOMOTION; MALE; MOTOR ACTIVITY; NEUROPATHIC PAIN; NONHUMAN; OSTEOARTHRITIS; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RAT;

ANALGESICS, NON-NARCOTIC; ANIMALS; ARTHRITIS, EXPERIMENTAL; CELLS, CULTURED; CONSTRICTION, PATHOLOGIC; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLOHEXANOLS; CYCLOPROPANES; HUMANS; HYPERALGESIA; IMMUNOSUPPRESSIVE AGENTS; JOINTS; MALE; MICROSCOPY, FLUORESCENCE; MORPHOLINES; MOTOR ACTIVITY; PAIN; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB2; SCIATICA;

EID: 38349177841     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707568     Document Type: Article

References (52)

1. Bennett GJ, Xie Y-K (1988). A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33: 87-107.
2. Bingham B, Jones PG, Uveges AJ, Kotnis S, Lu P, Smith VA et al. (2007). Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers. Br J Pharmacol 151: 1061-1070.
3. Bonhaus DW, Chang LK, Kwan J, Martin GR (1998). Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J Pharmacol Exp Ther 287: 884-888.
4. Brennan TJ, Vandermeulen EP, Gebhart GF (1996). Characterization of a rat model of incisional pain. Pain 64: 493-501.
5. Chandran P, Hsieh GC, Pai M, Lee L, Faltynek C, Decker MW et al. (2006). TRPV1 receptor mediates the modulation of a novel activity-induced pain behavior in a rat model of osteoarthritis. Soc Neurosci Abstr 32: 642.12.
6. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh L (1994). Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53: 55.
7. Combe R, Bramwell S, Field MJ (2004). The monosodium iodoacetate model of osteoarthritis: a model of chronic nociceptive pain in rats? Neurosci Lett 370: 236-240.
8. Dixon WJ (1980). Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 20: 441-462.
9. Elmes SJR, Jhaveri MD, Smart D, Kendall DA, Chapman V (2004). Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naive rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci 20: 2311-2320.
10. Elmes SJR, Winyard LA, Medhurst SJ, Clayton NM, Wilson AW, Kendall DA et al. (2005). Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat. Pain 118: 327-335.
11. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O et al. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48: 443-450.
12. Fox A, Bevan S (2005). Therapeutic potential of cannabinoid receptor agonists as analgesic agents. Exp Opin Investig Drugs 14: 695-703.
13. Gallant M, Dufresne C, Gareau Y, Guay D, Leblanc Y, Prasit P et al. (1996). New class of potent ligands for the human peripheral cannabinoid receptor. Bioorg Med Chem Lett 6: 2263-2268.
14. Giblin GMP, O'shaughnessy CT, Naylor A, Mitchell WL, Eatherton AJ, Slingsby BP et al. (2007). Discovery of 2-[(2,4-dichlorophenyl) amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl) -5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. J Med Chem 50: 2597-2600.
15. Guingamp C, Gegout-Pottie P, Philippe L, Terlain B, Netter P, Gillet P (1997). Mono-iodoacetate-induced experimental osteoarthritis: a dose-response study of loss of mobility, morphology, and biochemistry. Arthritis Rheum 40: 1670-1679.
16. Guzman RE, Evans MG, Bove S, Morenko B, Kilgore K (2003). Monoiodoacetate-induced histologic changes in subchondral bone and articular cartilage of rat femorotibial joints: an animal model of osteoarthritis. Toxicol Pathol 31: 619-624.
17. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M et al. (1999). HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc Natl Acad Sci US A 96: 14228-14233.
18. Hargreaves K, Dubner R, Brown F, Flores C, Joris J (1988). A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32: 77-88.
19. Hohmann AG, Farthing JN, Zvonok AM, Makriyannis A (2004). Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther 308: 446-453.
20. 35S]GTPgS binding in the mouse brain. Eur J Pharmacol 321: R1-R3.
21. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161-202.
22. Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL et al. (1999). 3-(1′,1′-Dimethylbutyl)-1-deoxy-D8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 7: 2905-2914.
23. Huffman JW, Zengin G, Wu M-J, Lu J, Hynd G, Bushell K et al. (2004). Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB1 and CB2 receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB2 receptor agonists. Bioorg Med Chem 13: 89-112.
24. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP et al. (2003a). Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100: 10529-10533.
25. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP et al. (2003b). Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100: 10529-10533.
26. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A et al. (2005). CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA 102: 3093-3098.
27. Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW et al. (2006). CB2 cannabinoid receptor mediation of antinociception. Pain 122: 36-42.
28. Labuda CJ, Koblish M, Little PJ (2005). Cannabinoid CB2 receptor agonist activity in the hindpaw incision. Eur J Pharmacol 527: 172-174.
29. Lunn CA, Fine JS, Rojas-Triana A, Jackson JV, Fan X, Kung TT et al. (2006). A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther 316: 780-788.
30. Mackie K (2006). Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 46: 101-122.
31. Makriyannis A, Deng H (2002). Preparation of CB2 cannabinoid receptor-selective cannabimimetic aminoalkylindoles, particularly (piperidinylmethyl)- and (morpholinylmethyl)indoles, and their use. In PCT Int Appl. University of Connecticut, USA, pp 31; pp WO20020129.
32. Malan TP, Ibrahim MM, Vanderah TW, Makriyannis A, Porreca F (2002). Inhibition of pain responses by activation of CB2 cannabinoid receptors. Chem Phys Lipids 121: 191-200.
33. Malan Jr TP, Ibrahim MM, Deng H, Liu Q, Mata HP, Vanderah T et al. (2001). CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 93: 239-245.
34. Malan Jr TP, Ibrahim Mohab M, Lai J, Vanderah Todd W, Makriyannis A, Porreca F (2003). CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol 3: 62-67.
35. Mukherjee S, Adams M, Whiteaker K, Daza A, Kage K, Cassar S et al. (2004). Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. Eur J Pharmacol 505: 1-9.
36. Nackley AG, Makriyannis A, Hohmann AG (2003a). Selective activation of cannabinoid CB2 receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 119: 747-757.
37. Nackley AG, Makriyannis A, Hohmann AG (2003b). A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 117: 659-670.
38. Pertwee RG (2001). Cannabinoid receptors and pain. Prog Neurobiol 63: 569-611.
39. Pomonis JD, Boulet JM, Gottshall SL, Phillips S, Sellers R, Bunton T et al. (2005). Development and pharmacological characterization of a rat model of osteoarthritis pain. Pain 114: 339-346.
40. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C et al. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350: 240-244.
41. Rinaldi-Carmona M, Barth F, Millan J, Derocq J-M, Casellas P, Congy C et al. (1998). SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284: 644-650.
42. Romero-Sandoval A, Eisenach JC (2007). Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision. Anesthesiology 106: 787-794.
43. Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A et al. (1999). Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol 126: 665-672.
44. Sagar DR, Kelly S, Millns PJ, O'shaughnessey CT, Kendall DA, Chapman V (2005). Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur J Neurosci 22: 371-379.
45. Spetea M, Nevin ST, Hosztafi SN, Ronai ASZ, Toth G, Borsodi A (1998). Affinity profiles of novel Î-receptor selective benzofuran derivatives of non-peptide opioids. Neurochem Res 23: 1211-1216.
46. Tao Q, Abood ME (1998). Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling. J Pharmacol Exp Ther 285: 651-658.
47. Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL et al. (2005). Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48: 658-672.
48. Whiteside GT, Gottshall SL, Boulet JM, Chaffer SM, Harrison JE, Pearson MS et al. (2005). A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. Eur J Pharmacol 528: 65-72.
49. Whiteside GT, Lee GP, Valenzano KJ (2007). The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. Curr Med Chem 14: 917-936.
50. Wotherspoon G, Fox A, Mcintyre P, Colley S, Bevan S, Winter J (2005). Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 135: 235-245.
51. Yao BB, Mukherjee S, Fan Y, Garrison TR, Daza AV, Grayson GK et al. (2006). In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? Br J Pharmacol 149: 145-154.
52. Zhang J, Hoffert C, Vu Huy K, Groblewski T, Ahmad S, O'donnell D (2003). Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 17: 2750-2754.